Glutathione (GSH) In The Treatment of Parkinson's Disease

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an investigator initiated pilot study to examine the effects of GSH in PD. The goal of this study is to acquire some basic data regarding side effects and efficacy of this compound to determine if this is a possible treatment option that could be recommended to interested PD patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of South Florida
• Collaborator: Wellness Health & Pharmaceuticals, Inc.

Criteria

Inclusion Criteria:

• Idiopathic Parkinson's disease (2 of 3 of the cardinal symptoms:tremor, bradykinesia, rigidity)

• Mini Mental State Examination > 24

• Anti-parkinsonian medications stable for one month

• Hoehn and Yahr II-IV

• Age 18 and above

Exclusion Criteria:

• Atypical parkinsonism

• History of seizure, drug addiction

• Use of typical neuroleptics

• Previous use of glutathione